SCHEMBL5047251

SCHEMBL5047251

COC(=O)c1ccc(/C=C/C(=O)c2cc(OCc3ccc(F)cc3)c3c(c2)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.48
RAB9A P51151 3/20 0.46
POLB P06746 2/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 6/20 0.46
MAPT P10636 5/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PKM P14618 1/20 0.43
BLM P54132 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 2/20 0.42
HTT P42858 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
CYP3A4 P08684 1/20 0.41
TNFRSF1A P19438 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047257 1.00 MAOB (0.48) MAOBRAB9APOLBUSP2LMNA
SCHEMBL5048445 0.91 MAOB (0.52) MAOBMEN1KMT2ATNFRSF1AGSK3B
SCHEMBL5048446 0.91 MAOB (0.52) MAOBMEN1KMT2ATNFRSF1AGSK3B
SCHEMBL5047173 0.84 MAOB (0.43) MAOBLMNAMEN1KMT2AALDH1A1
SCHEMBL5047177 0.84 MAOB (0.43) MAOBLMNAMEN1KMT2AALDH1A1
SCHEMBL5047090 0.81 CYP3A4 (0.43) MAOBRAB9ALMNAMAPTKMT2A
SCHEMBL5047204 0.79 LMNA (0.52) MAOBRAB9ALMNAMAPTMEN1
SCHEMBL5047202 0.79 LMNA (0.52) MAOBRAB9ALMNAMAPTMEN1
SCHEMBL4946956 0.77 MAPT (0.41) MAOBRAB9ALMNAMAPTMEN1
SCHEMBL5047066 0.76 AKR1C3 (0.42) MAOBLMNATNFRSF1AALDH1A1CXCL12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed
EP-1513803-A1 LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS Galderma Research & Development, S.N.C. (FR) 2005-03-16 EP disclosed
WO-2003101945-A1 LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG MAOB 2084/4885RAB9A 1437/4885POLB 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.